Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Rank in Stocks #173
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Share Price
$62.26
Last synced: 2026-09-22
Market Cap
$127.18B
Change (1 day)
-0.78%
Change (1 year)
38.63%
Country
US
Trade Bristol-Myers Squibb Company (BMY)

Category

Price of BMY with the market cap of B
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$62.26
Market Capitalization of Bristol-Myers Squibb Company(BMY)
Market Cap: $127.18B
As of September 2026 Bristol-Myers Squibb Company has a market cap of $127.18B. This makes Bristol-Myers Squibb Company the world's 173rd most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Bristol-Myers Squibb Company from 1968 to 2026
BMY compared with Top 5 Most Popular stocks
Price of BMY Asset B Mkt. of B Results
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
$2,718.76 $127.18B
$5.554T +4,266.78%
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
$2,443.78 $127.18B
$4.992T +3,825.12%
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
$2,071.18 $127.18B
$4.231T +3,226.66%
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
$1,811.58 $127.18B
$3.701T +2,809.70%
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
$1,347.17 $127.18B
$2.752T +2,063.78%